论文部分内容阅读
目的探讨阿奇霉素联合阿糖腺苷治疗小儿病毒性肺炎的临床效果及安全性。方法选取124例病毒性肺炎患儿随机分为观察组和对照组各62例,对照组给予利巴韦林治疗,观察组予以阿奇霉素联合阿糖腺苷治疗,比较两组治疗后的临床效果及不良反应。结果观察组临床治疗总有效率为93.65%,显著高于对照组的83.87%,差异有统计学意义(P<0.05);观察组退热、咳嗽、啰音及肺X线浸润影等消失时间均少于对照组,差异有统计学意义(P<0.05);观察组平均住院时间(7.84±2.18)天显著少于对照组的(10.62±2.71)天,差异有统计学意义(P<0.05);对照组治疗期间出现不良反应4例,发生率为6.45%,观察组为6例,发生率为9.52%,两组差异无统计学意义(P>0.05)。结论阿奇霉素联合阿糖腺苷治疗小儿病毒性肺炎临床疗效显著,可有效缩短患儿的治疗时间,值得临床推广应用。
Objective To investigate the clinical effect and safety of azithromycin combined with vidarabine in the treatment of children with viral pneumonia. Methods A total of 124 children with viral pneumonia were randomly divided into observation group and control group with 62 cases in each group. The control group was given ribavirin. The observation group was treated with azithromycin plus vidarabine. The clinical effects of the two groups were compared. Adverse reactions. Results The total effective rate of clinical observation in observation group was 93.65%, which was significantly higher than 83.87% in control group (P <0.05). The disappearance time of fever, cough, rales and pulmonary X-ray infiltration in the observation group (P <0.05). The average length of hospital stay in the observation group (7.84 ± 2.18 days) was significantly lower than that in the control group (10.62 ± 2.71 days), with significant difference (P <0.05) ). There were 4 adverse reactions in the control group during the treatment period, the incidence rate was 6.45%, the observation group was 6 cases, the incidence rate was 9.52%. There was no significant difference between the two groups (P> 0.05). Conclusion Azithromycin combined with vidarabine treatment of children with viral pneumonia clinical significant effect, which can effectively shorten the treatment of children, it is worth promoting the clinical application.